Patient Rating:

No Rating Available?

Djordje Atanackovic, M.D.

Patient Rating:

No Rating Available?

Specialties

  • Hematology/BMT
  • Myeloma
  • Plasmacytoma
  • Plasma Cell Leukemia
  • Amyloidosis
  • Cancer Immunotherapy
  • Tumor Immunology

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address

Specialties

  • Hematology/BMT
  • Myeloma
  • Plasmacytoma
  • Plasma Cell Leukemia
  • Amyloidosis
  • Cancer Immunotherapy
  • Tumor Immunology

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions Hematology/BMT
Board Certification Hamburg Medical Council (Sub: Oncology/Hematology)

Academic Profile

Research Interests

  • Diagnosis and Treatment of Patients with B-cell Lymphoma
  • Management of Lung Cancer Patients
  • Diagnosis and Treatment of Patients with Multiple Myeloma Including High-dose Chemotherapy Plus Autologous Stem Cell Transplantation

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions Hematology/BMT
Board Certification Hamburg Medical Council (Sub: Oncology/Hematology)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-3229 School of Medicine
Hematology
30 N Medical Dr
Salt Lake City, UT 84132

Education

Education History

Type School Degree
Fellowship University Medical Center Hamburg-Eppendorf
Oncology/Hematology/Stem Cell Transplantation
Clinical/Research Fellow
Postdoctoral Fellowship New York branch of the Ludwig Institute for Cancer Research
Postdoctoral Fellow
Residency University Medical Center Hamburg-Eppendorf, Department of Oncology/Hematology
Internal Medicine
Resident
Professional Medical Benjamin Franklin University Hospital
Psychosomatic Medicine
M.D.
Internship University of Chicago
Internal Medicine
Intern
Internship University of California San Diego
Intern
Internship Hotel Dieu de
Surgery
Intern
Doctoral Training Free University Berlin
Medical Studies
Doctoral Training University of Hannover
Medical Studies

Publications

Selected Provider Publications

Journal Article

  1. Kroger N, Stubig T, Atanackovic D (2014). Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 20(2), 168-72.
  2. Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS (2014). Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer, 135(5), 1142-52.
  3. Berdien B, Mock U, Atanackovic D, Fehse B (2014). TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther, 21(6), 539-48.
  4. Stubig T, Badbaran AAUID- ORCID 0000-0002-9993-0886, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM, Fehse B, Kroger N (2014). 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm, 2014, 418292.
  5. Braga WM, da Silva BR, Alves VL, Bortoluzo AB, Atanackovic D, Colleoni GW (2014). Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma? Immunotherapy, 6(5), 569-75.
  6. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kroger N, Atanackovic D (2014). Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother, 63(11), 1151-62.
  7. Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW (2014). FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother, 63(11), 1189-97.
  8. Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kroger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S (2014). Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.LID - 10.1038/leu.2014.236 [doi]. Leukemia.
  9. Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Woll E, Ulrich A, Fischer R, Kruger C, Schuhmacher C (2014). A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer.
  10. Kroger N, Zabelina T, Klyuchnikov E, Kropff M, Pfluger KH, Burchert A, Stubig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR (2013). Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant, 48(3), 403-7.
  11. Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stubig T, Fehse B, Zander AR (2013). Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant, 19(3), 398-404.
  12. Wolschke C, Stubig T, Hegenbart U, Schonland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kroger N (2013). Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol, 41(2), 134-142.e3.
  13. Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK, Klose H, Simon R, Pantel K, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W (2013). Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer, 79(3), 221-7.
  14. Atanackovic D, Nowottne U, Freier E, Weber CS, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kroger N, Brunner-Weinzierl MC, Bokemeyer C, Deter HC (2013). Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders. Stress, 16(4), 421-8.
  15. Berdien B, Reinhard H, Meyer S, Spock S, Kroger N, Atanackovic D, Fehse B (2013). Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother, 9(6), 1205-16.
  16. Atanackovic D, Reinhard H, Meyer S, Spock S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kroger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C (2013). The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother, 9(12), 2533-42.
  17. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kroger N, Atanackovic D (2012). Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol, 2012, 134081.
  18. Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kroger N (2012). Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst, 104(13), 1005-20.
  19. Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W (2012). Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol, 25(12), 1566-73.

Review

  1. Atanackovic D, Luetkens T, Kroger N (2014). Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. [Review]. Leukemia, 28(5), 993-1000.
  2. Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D (2013). CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. [Review]. Lung Cancer, 80(3), 242-8.
  3. Atanackovic D, Schilling G (2013). Second autologous transplant as salvage therapy in multiple myeloma. [Review]. Br J Haematol, 163(5), 565-72.
  4. Braga WM, Atanackovic D, Colleoni GW (2012). The role of regulatory T cells and TH17 cells in multiple myeloma. [Review]. Clin Dev Immunol, 2012, 293479.

Case Report

  1. Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D (2014). Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol, 99(1), 91-4.

Letter

  1. Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kroger N, Atanackovic D (2014). Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients [Letter to the editor]. Blood Cancer J, 4, e212.
  2. Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M (2013). MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients [Letter to the editor]. Leukemia, 27(8), 1767-9.

Patent

  1. US Patent 7803382 (Pending). “Colon cancer antigen panel - The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject”. U.S. Patent No. Old LJ, Gnjatic S, Atanackovic D, Cerundolo V, Ling KL. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Atanackovic D, Luetkens T (Pending). “Diagnosis and therapy of hematological malignancies”. U.S. Patent No. U.S. Patent application 61/254852. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Atanackovic D, Krger N (Pending). “IL-16 as a target for the diagnosis and therapy of haematological malignancies and solid tumors”. U.S. Patent No. U.S. Patent application 12/716481. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Gnjatic S, Atanackovic D, Old LJ (Pending). “Isolated NY-ESO-1 peptides which bind to HLA class II molecules and uses thereof”. U.S. Patent No. U.S. Patent application 10/556853. Washington, D.C.:U.S. Patent and Trademark Office.

Clinical Trials

Video & News